CN118146317A - Adeno-associated virus capsid protein and application thereof - Google Patents
Adeno-associated virus capsid protein and application thereof Download PDFInfo
- Publication number
- CN118146317A CN118146317A CN202211567051.3A CN202211567051A CN118146317A CN 118146317 A CN118146317 A CN 118146317A CN 202211567051 A CN202211567051 A CN 202211567051A CN 118146317 A CN118146317 A CN 118146317A
- Authority
- CN
- China
- Prior art keywords
- aav
- vector
- cell
- viral
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000565 Capsid Proteins Proteins 0.000 title claims abstract description 53
- 102100023321 Ceruloplasmin Human genes 0.000 title claims abstract description 53
- 241000702421 Dependoparvovirus Species 0.000 title claims abstract description 24
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 125
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 241000700605 Viruses Species 0.000 claims description 102
- 239000013603 viral vector Substances 0.000 claims description 72
- 108091033319 polynucleotide Proteins 0.000 claims description 47
- 102000040430 polynucleotide Human genes 0.000 claims description 47
- 239000002157 polynucleotide Substances 0.000 claims description 47
- 239000008194 pharmaceutical composition Substances 0.000 claims description 40
- 230000003612 virological effect Effects 0.000 claims description 39
- 230000001225 therapeutic effect Effects 0.000 claims description 27
- 239000013604 expression vector Substances 0.000 claims description 23
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 19
- 239000002773 nucleotide Substances 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 208000002780 macular degeneration Diseases 0.000 claims description 11
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 11
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 10
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 8
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 7
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 7
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 208000017442 Retinal disease Diseases 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 201000005667 central retinal vein occlusion Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000030533 eye disease Diseases 0.000 claims description 4
- 230000000670 limiting effect Effects 0.000 claims description 4
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 4
- 208000024304 Choroidal Effusions Diseases 0.000 claims description 3
- 208000007135 Retinal Neovascularization Diseases 0.000 claims description 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 3
- 201000011190 diabetic macular edema Diseases 0.000 claims description 3
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 208000032253 retinal ischemia Diseases 0.000 claims description 3
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims description 2
- 230000002137 anti-vascular effect Effects 0.000 claims description 2
- 239000013607 AAV vector Substances 0.000 abstract description 17
- 230000035772 mutation Effects 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 95
- 239000013598 vector Substances 0.000 description 80
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 53
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 52
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 52
- 238000002347 injection Methods 0.000 description 29
- 239000007924 injection Substances 0.000 description 29
- 238000000034 method Methods 0.000 description 29
- 239000002245 particle Substances 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- 230000002207 retinal effect Effects 0.000 description 21
- 239000005557 antagonist Substances 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- 229920001184 polypeptide Polymers 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 17
- 210000001508 eye Anatomy 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 108091030071 RNAI Proteins 0.000 description 14
- 230000009368 gene silencing by RNA Effects 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 13
- 239000005090 green fluorescent protein Substances 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 238000004806 packaging method and process Methods 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 108091008605 VEGF receptors Proteins 0.000 description 9
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 9
- 210000005252 bulbus oculi Anatomy 0.000 description 9
- 108091023037 Aptamer Proteins 0.000 description 8
- 241000288906 Primates Species 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000013608 rAAV vector Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 208000022873 Ocular disease Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 230000002452 interceptive effect Effects 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000004055 small Interfering RNA Substances 0.000 description 6
- 241000701161 unidentified adenovirus Species 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 210000002845 virion Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 101710197658 Capsid protein VP1 Proteins 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 241000714474 Rous sarcoma virus Species 0.000 description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 108091008695 photoreceptors Proteins 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 3
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 3
- 208000006992 Color Vision Defects Diseases 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 3
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 3
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 3
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102000015336 Nerve Growth Factor Human genes 0.000 description 3
- 108010015406 Neurturin Proteins 0.000 description 3
- 102100021584 Neurturin Human genes 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 3
- 102000004330 Rhodopsin Human genes 0.000 description 3
- 108090000820 Rhodopsin Proteins 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 229940053128 nerve growth factor Drugs 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 210000000608 photoreceptor cell Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000003994 retinal ganglion cell Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- -1 2-mercaptoethanol Chemical compound 0.000 description 2
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- CUKSFECWKQBVED-INIZCTEOSA-N Decursin Chemical compound C1=CC(=O)OC2=C1C=C1C[C@H](OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-INIZCTEOSA-N 0.000 description 2
- BGXFQDFSVDZUIW-UHFFFAOYSA-N Decursinol Natural products O1C(=O)C=CC2=C1C=C1OC(C)(C)C(O)CC1=C2 BGXFQDFSVDZUIW-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000714165 Feline leukemia virus Species 0.000 description 2
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- CUKSFECWKQBVED-UHFFFAOYSA-N Grandivittin Natural products C1=CC(=O)OC2=C1C=C1CC(OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 101001104102 Homo sapiens X-linked retinitis pigmentosa GTPase regulator Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
- 241001071917 Lithospermum Species 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 102000010175 Opsin Human genes 0.000 description 2
- 108050001704 Opsin Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
- 101710150114 Protein rep Proteins 0.000 description 2
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101710152114 Replication protein Proteins 0.000 description 2
- 201000007737 Retinal degeneration Diseases 0.000 description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 2
- 102100040092 X-linked retinitis pigmentosa GTPase regulator Human genes 0.000 description 2
- MXANJRGHSFELEJ-MRXNPFEDSA-N [(1r)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] 3-hydroxy-3-methylbutanoate Chemical compound C1=CC(O)=C2C(=O)C([C@H](OC(=O)CC(C)(C)O)CC=C(C)C)=CC(=O)C2=C1O MXANJRGHSFELEJ-MRXNPFEDSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 description 2
- 210000000411 amacrine cell Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960003005 axitinib Drugs 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- MXANJRGHSFELEJ-UHFFFAOYSA-N beta:-hydroxy isovaleryl shikonin Natural products C1=CC(O)=C2C(=O)C(C(OC(=O)CC(C)(C)O)CC=C(C)C)=CC(=O)C2=C1O MXANJRGHSFELEJ-UHFFFAOYSA-N 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- JXZWWIMXTVJNSF-UHFFFAOYSA-N decursin Natural products CC(=CC(=O)OC1Oc2cc3OC(=O)C=Cc3cc2CC1(C)C)C JXZWWIMXTVJNSF-UHFFFAOYSA-N 0.000 description 2
- BGXFQDFSVDZUIW-LBPRGKRZSA-N decursinol Chemical compound O1C(=O)C=CC2=C1C=C1OC(C)(C)[C@@H](O)CC1=C2 BGXFQDFSVDZUIW-LBPRGKRZSA-N 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000013534 fluorescein angiography Methods 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000002287 horizontal cell Anatomy 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
- 229960000639 pazopanib Drugs 0.000 description 2
- YJGVMLPVUAXIQN-HAEOHBJNSA-N picropodophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-HAEOHBJNSA-N 0.000 description 2
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
- 229960003876 ranibizumab Drugs 0.000 description 2
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 2
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- 241001075517 Abelmoschus Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WPTTVJLTNAWYAO-KPOXMGGZSA-N Bardoxolone methyl Chemical compound C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C WPTTVJLTNAWYAO-KPOXMGGZSA-N 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 208000035545 CNGA3-related retinopathy Diseases 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 208000036693 Color-vision disease Diseases 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 229910001006 Constantan Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010012692 Diabetic uveitis Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 208000001351 Epiretinal Membrane Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091004242 G-Protein-Coupled Receptor Kinase 1 Proteins 0.000 description 1
- 102000004437 G-Protein-Coupled Receptor Kinase 1 Human genes 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- WDXRGPWQVHZTQJ-AUKWTSKRSA-N Guggulsterone Natural products C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=O)/C(=C/C)[C@@]1(C)CC2 WDXRGPWQVHZTQJ-AUKWTSKRSA-N 0.000 description 1
- WDXRGPWQVHZTQJ-NRJJLHBYSA-N Guggulsterone E Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=O)C(=CC)[C@@]1(C)CC2 WDXRGPWQVHZTQJ-NRJJLHBYSA-N 0.000 description 1
- 241001348514 Hamus Species 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000714192 Human spumaretrovirus Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 101150105817 Irbp gene Proteins 0.000 description 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
- 108700036276 KH902 fusion Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108050006600 Metalloproteinase inhibitor 3 Proteins 0.000 description 1
- 208000010164 Multifocal Choroiditis Diseases 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102000003683 Neurotrophin-4 Human genes 0.000 description 1
- 108090000099 Neurotrophin-4 Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102100040681 Platelet-derived growth factor C Human genes 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010064714 Radiation retinopathy Diseases 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 108090000799 Rhodopsin kinases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 102000012753 TIE-2 Receptor Human genes 0.000 description 1
- 108010090091 TIE-2 Receptor Proteins 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- PRYZSLKPMFOUNL-MHIBGBBJSA-N bevasiranib Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C(NC(=O)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 PRYZSLKPMFOUNL-MHIBGBBJSA-N 0.000 description 1
- 229950006615 bevasiranib Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000010018 blue color blindness Diseases 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229950005748 conbercept Drugs 0.000 description 1
- 238000000942 confocal micrograph Methods 0.000 description 1
- 208000006623 congenital stationary night blindness Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 description 1
- 229960000588 flunixin Drugs 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229950000700 guggulsterone Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000050995 human FLT1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- IXAQOQZEOGMIQS-SSQFXEBMSA-N lipoxin A4 Chemical compound CCCCC[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC(O)=O IXAQOQZEOGMIQS-SSQFXEBMSA-N 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108010017992 platelet-derived growth factor C Proteins 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 201000000763 red color blindness Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000964 retinal cone photoreceptor cell Anatomy 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000004283 retinal dysfunction Effects 0.000 description 1
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 1
- 102000029752 retinol binding Human genes 0.000 description 1
- 108091000053 retinol binding Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091008601 sVEGFR Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- WDXRGPWQVHZTQJ-UHFFFAOYSA-N trans-guggulsterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CC(=O)C(=CC)C1(C)CC2 WDXRGPWQVHZTQJ-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The application discloses an adeno-associated virus (AAV) capsid protein comprising the amino acid sequence shown in SEQ ID NO. 1. The application introduces point mutation into AAV capsid protein, and adopts AAV vector assembled by mutated capsid protein, so that the efficiency of expressing target protein by the assembled AAV vector is obviously improved.
Description
Technical Field
The application belongs to the field of viral vectors, and particularly relates to a modified adeno-associated virus capsid protein and application thereof.
Background
Currently, gene therapy is a research hotspot in the biomedical field, and vectors most commonly used in gene therapy include adenovirus, lentivirus and adeno-associated virus (AAV, supra). The wild-type adeno-associated virus (wtAAV, hereinafter the same) belongs to the parvoviridae, is a single-stranded DNA virus with the diameter of 20nm, is in an icosahedron, and is coated with a viral genome with inverted terminal repeat sequences (ITRs, hereinafter the same) at two ends in capsid proteins, and an open reading frame ORF is arranged between ITRs, and comprises capsid proteins Cap, replication proteins Rep and package activation proteins AAP. Wild-type adeno-associated virus is known to integrate into the human chromosomal AAVS1 site. The recombinant adeno-associated virus (rAAV, the same applies hereinafter) genome sequence only retains ITRs at both ends necessary for packaging the virus, and the middle is replaced by the target gene sequence, thus ensuring that the virus genome is not integrated into the host genome.
Compared with adenoviruses and lentiviruses, the recombinant adeno-associated virus (recombinant adeno-associatedvirus, rAAV, the same applies below) has lower probability of inducing immune response in human body, which is helpful for improving the efficiency of vector delivery of target genes, and the use of rAAV can reduce toxicity risks from immune association; in addition, rAAV can effectively mediate the continuous and stable expression of exogenous genes in vitro and in vivo for a long period, and has become one of the most promising gene therapy vectors.
Studies show that the capsid of the adeno-associated virus is closely related to the infectivity and tissue affinity of the virus, so that the infection and expression efficiency of the adeno-associated virus vector in different cells, tissues and organs are greatly influenced, and therefore, the improvement and optimization of the capsid protein of the adeno-associated virus is beneficial to improving the expression efficiency and the drug effect of the adeno-associated virus vector.
Disclosure of Invention
The application aims to provide a modified adeno-associated virus capsid protein and application thereof.
The application provides the following technical scheme for solving the technical problems:
in a first aspect the application provides an adeno-associated viral capsid protein comprising the amino acid sequence shown in SEQ ID No. 1.
In a second aspect the application provides a polynucleotide molecule comprising at least one of the nucleotide sequences encoding the adeno-associated viral capsid proteins provided in the first aspect of the application or the complement thereof; preferably, the polynucleotide molecule comprises the nucleotide sequence shown in SEQ ID NO. 3.
In a third aspect the application provides an expression vector comprising a polynucleotide molecule provided in accordance with the second aspect of the application, wherein the polynucleotide molecule is operably linked to a promoter sequence.
In a fourth aspect, the application provides a cell comprising a polynucleotide molecule provided in accordance with the second aspect of the application or an expression vector provided in accordance with the third aspect of the application.
In a fifth aspect the present application provides a recombinant virus or viral vector comprising an adeno-associated viral capsid protein provided by the first aspect of the application; preferably, the recombinant virus or viral vector is an AAV; more preferably, the AAV is AAV2.
In a sixth aspect, the application provides a pharmaceutical composition comprising a recombinant virus or viral vector as provided in the fifth aspect of the application, and a pharmaceutically acceptable carrier and/or excipient.
The seventh aspect of the application provides the use of an adeno-associated viral capsid protein of the first aspect of the application, a polynucleotide molecule of the second aspect of the application, an expression vector of the third aspect of the application, a cell of the fourth aspect of the application, a recombinant virus or viral vector of the fifth aspect of the application or a pharmaceutical composition of the sixth aspect of the application in the manufacture of a medicament for the treatment of neovascular ocular disease.
The eighth aspect of the application also provides a method of treating or preventing a neovascular ocular disease comprising administering to a subject a recombinant virus or viral vector of the fifth aspect of the application or a pharmaceutical composition of the sixth aspect of the application by intravitreal injection or suprachoroidal injection.
The application has the beneficial effects that: the application introduces point mutation into AAV capsid protein, and adopts AAV vector assembled by mutated capsid protein, so that the efficiency of expressing target protein by the assembled AAV vector is obviously improved.
Drawings
FIG. 1 is a fluorescence micrograph of HEK293 cells infected with a viral vector.
FIG. 2 is a comparison of the percentage of GFP positive expression cells from HEK293 cells infected with different viral vectors as analyzed by flow cytometry.
FIG. 3 is a confocal micrograph of GFP expressed by eyeballs of a virus vector infected mice.
Detailed Description
In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described, and it is apparent that the drawings in the description below are only one embodiment of the present application, and other embodiments may be obtained according to these drawings by those skilled in the art.
Definition of the definition
As used herein, the terms "a" and "an" and "the" and similar referents refer to the singular and the plural, unless the context clearly dictates otherwise.
As used herein, the terms "about," "substantially" and "similar to" refer to an acceptable error range for a particular value as determined by one of ordinary skill in the art, which error range may depend in part on the manner in which the value is measured or determined, or on the limitations of the measurement system.
As used herein, "vector" refers to a macromolecule or association of macromolecules that comprises or is associated with a polynucleotide molecule, and that can be used to mediate delivery of the polynucleotide molecule to a cell. Exemplary vectors include, for example, plasmids, viral vectors, liposomes, and other gene delivery vehicles.
The term "AAV" is an abbreviation for adeno-associated virus and may be used to refer to the virus itself or derivatives thereof. Unless otherwise indicated, the term encompasses all subtypes as well as naturally occurring forms and recombinant forms. The term "AAV" encompasses AAV type 1 (AAV-1), AAV type 2 (AAV-2), AAV type 3 (AAV-3), AAV type 4 (AAV-4), AAV type 5 (AAV-5), AAV type 6 (AAV-6), AAV type 7 (AAV-7), AAV type 8 (AAV-8), avian AAV, bovine AAV, canine AAV, equine AAV, primate AAV, non-primate AAV, ovine AAV, and the like. Illustratively, "primate AAV" refers to an AAV that infects a primate, "non-primate AAV" refers to an AAV that infects a non-primate mammal, "bovine AAV" refers to an AAV that infects a bovine mammal, and so forth.
Genomic sequences, natural Terminal Repeat (TR) sequences, rep protein sequences, and capsid subunit sequences of various serotypes of AAV are known in the art. Such sequences can be found in the literature or in public databases such as GenBank. See, e.g., genBank accession numbers NC_002077(AAV-1)、AF063497(AAV-1)、NC_001401(AAV-2)、AF043303(AAV-2)、NC_001729(AAV-3)、NC_-001829(AAV-4)、U89790(AAV-4)、NC_006152(AAV-5)、AF028704 and AAB95450 (AAV-6), AF513851 (AAV-7), AF513852 (AAV-8), and NC_006261 (AAV-8), the disclosures of which are incorporated herein by reference for teaching AAV nucleic acid and amino acid sequences. See, e.g., SRIVISTAVA et al (1983) J.virology 45:555; chiorini et al (1998) J.Virol.71:6823; chiorini et al (1999) J.Virol.73:1309; bantel-Schaal et al (1999) J.Virol.73:939; xiao et al (1999) J.Virol.73:3994; murammatsu et al (1996) journal virology 221:208; shade et al (1986) J virology 58:921; gao et al (2002) Proc. Nat. Acad. Sci. USA, 99:11854; moris et al (2004) Virology (Virology) 33:375-383; international patent publications WO 00/28061, WO 99/61601 and WO 98/11244; U.S. patent No. 6,156,303. In addition, polynucleotide sequences encoding any capsid protein can be readily generated based on the amino acid sequences, including codon optimized sequences, and known genetic codes.
"AAV virions" or "AAV viral particles" or "AAV viral vectors" or "AAV vector particles" or "AAV particles" refer to viral particles comprised of at least one AAV capsid protein and a encapsidated polynucleotide AAV vector. Thus, production of AAV vector particles necessarily includes production of AAV vectors, as such vectors are contained within AAV vector particles.
The abbreviation "rAAV" refers to recombinant adeno-associated virus, also known as recombinant AAV vector (or "rAAV vector"). As used herein, a "rAAV vector" refers to an AAV vector that includes polynucleotide sequences that are not of AAV origin (i.e., polynucleotides heterologous to AAV), which are typically sequences of interest when genetically transforming a cell. Typically, the heterologous polynucleotide is flanked by at least one, and typically two AAV Inverted Terminal Repeats (ITRs). The term rAAV vector encompasses both rAAV vector particles and rAAV vector plasmids.
"Packaging" refers to a series of intracellular events that result in the assembly and encapsidation of AAV particles.
AAV "rep" and "cap" genes refer to polynucleotide sequences encoding replication and capsid proteins of adeno-associated viruses. AAV rep and cap are referred to herein as AAV "packaging genes".
"Helper virus" of an AAV refers to a virus that allows the AAV (e.g., wild-type AAV) to be replicated and packaged by mammalian cells. Various helper viruses for AAV are known in the art, including, for example, poxviruses such as adenovirus, herpes virus, and vaccinia. Adenovirus encompasses many different subgroups, but adenovirus type 5 in subgroup C is most commonly used. Many adenoviruses of human, non-human mammalian and avian origin are known and available from storage institutions such as ATCC. Viruses of the herpes family include, for example, herpes Simplex Virus (HSV) and Ai Bashi virus (EBV), cytomegalovirus (CMV) and pseudorabies virus (PRV); the virus may also be obtained from a storage facility such as ATCC.
An "infectious" virus or viral particle refers to a virus or viral particle that includes a properly assembled viral capsid and is capable of delivering a polynucleotide component into a cell. The term does not necessarily imply that the virus has any replication capacity. Assays for counting infectious viral particles are described in the present application and elsewhere in the art. Viral infectivity can be expressed as the ratio of infectious viral particles to total viral particles. Methods for determining the ratio of infectious viral particles to total viral particles are known in the art. See, e.g., grainger et al (2005) molecular therapy (mol. Thor.) 11:s337 (describing TCID50 infection titer assays); zolotukhin et al (1999) Gene therapy (Gene Ther.) 6:973.
"Replication-competent)" virus (e.g., replication-competent AAV) refers to a phenotypic wild-type virus that is infectious and capable of replication in an infected cell (i.e., in the presence of helper or helper functions). In the case of AAV, replication capacity typically requires the presence of functional AAV packaging genes. In general, the recombinant viruses or viral vectors described herein are replication-incompetent in mammalian cells (especially in human cells) due to the lack of one or more AAV packaging genes, even in the presence of helper functions; typically, the recombinant viruses or viral vectors of the application lack AAV packaging gene sequences, thereby minimizing the possibility of recombining AAV packaging genes with the incoming rAAV vector to produce replication competent AAV (rcAAV). In most cases, a recombinant virus or viral vector (which may also be referred to as a rAAV vector, rAAV viral particle, etc.) formulation as described herein contains little, if any, replication competent AAV (e.g., less than about 1rcAAV/10 2 rAAV particles, less than about 1rcAAV/10 4 rAAV particles, less than about 1rcAAV/10 8 rAAV particles, less than about 1rcAAV/10 12 rAAV particles, or no rcAAV).
The term "polynucleotide molecule" refers to a polymeric form of nucleotides of any length, or analogs thereof, comprising deoxyribonucleotides or ribonucleotides. The polynucleotide molecules may include modified nucleotides, such as methylated nucleotides and nucleotide analogs, and may be separated by non-nucleotide components. Modification of the nucleotide structure, if present, may be performed before or after assembly of the polymer. As used herein, the term polynucleotide molecule refers interchangeably to double-stranded molecules and single-stranded molecules. Unless otherwise indicated or required, the polynucleotide molecules described herein encompass both double stranded forms, as well as each single stranded form known or predicted to constitute two complementary single stranded forms of the double stranded forms.
"Gene" refers to a polynucleotide containing at least one open reading frame capable of encoding a particular gene product after transcription and sometimes translation. The term "gene" or "coding sequence" refers to an in vitro or in vivo nucleotide sequence that encodes a gene product. In some cases, the gene consists of or consists essentially of a coding sequence, i.e., a sequence that encodes a gene product. In other cases, the gene includes additional non-coding sequences. For example, a gene may or may not contain regions preceding and following the coding region, such as a 5' untranslated region (5 ' utr) or "leader" sequence or a 3' utr or "trailer" sequence, as well as intervening sequences (introns) between individual coding segments (exons).
A "gene product" is a molecule that results from the expression of a particular gene. Gene products include, for example, polypeptides, aptamers, interfering RNAs, mRNAs, and the like. In particular embodiments, a "gene product" is a polypeptide, peptide, protein, or interfering RNA, including short interfering RNA (siRNA), miRNA, or small hairpin RNA (shRNA). In particular embodiments, the gene product is a therapeutic gene product, such as a therapeutic protein.
As used herein, "therapeutic gene" refers to a gene that, when expressed, produces a therapeutic gene product that imparts a beneficial effect on cells or tissues in which the therapeutic gene product is present, or on a mammal in which the therapeutic gene is expressed. Examples of beneficial effects include improving the sign or symptom of a condition or disease, preventing or inhibiting a condition or disease, or imparting a desired characteristic. Therapeutic genes include, but are not limited to, genes that correct genetic defects in cells or mammals.
As used herein, a "transgene" is a gene that is delivered to a cell by a vector.
A "control element" or "control sequence" is a nucleotide sequence that is involved in the interaction of a molecule that aids in the regulation of a function of a polynucleotide, including, for example, replication, transcription, splicing, translation, or degradation of the polynucleotide. Modulation can affect the frequency, speed, or specificity of the process and can be enhancing or inhibitory in nature. Control elements known in the art include, for example, transcriptional regulatory sequences, such as promoters and enhancers. Promoters are regions of DNA that are capable of binding RNA polymerase under certain conditions and that initiate transcription from a coding region that is typically downstream (in the 3' direction) of the promoter.
As used herein, the term "operably linked" refers to two components that have been placed into a functional relationship with each other. The term "operably linked" when used in reference to a regulatory sequence and a coding sequence means that the regulatory sequence affects the expression of the linked coding sequence. "regulatory sequence", "regulatory element", or "control element" refers to a nucleic acid sequence that affects the cycle and level/amount of transcription, RNA processing or stability, or translation of a related coding sequence. Regulatory sequences may include promoters; translation leader sequence; 5 'and 3' untranslated regions, introns; an enhancer; a stem-loop structure; a inhibitor binding sequence; a termination sequence; polyadenylation recognition sequences, and the like. Specific regulatory sequences may be located upstream and/or downstream of the coding sequence to which they are operably linked. Also, specific regulatory sequences operably linked to the coding sequence may be located on the relevant complementary strand of the double stranded nucleic acid molecule. Ligation may be accomplished by ligation (ligation) at appropriate restriction sites. If such sites are not present, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. However, the operatively connected elements need not be contiguous.
By "heterologous" is meant an entity of a genotype different from the rest of the entity it is compared to. For example, polynucleotides introduced into plasmids or vectors derived from different species by genetic engineering techniques are heterologous polynucleotides. Promoters that are removed from their native coding sequences and are operably linked to coding sequences that are not found in native linkage to the promoter are heterologous promoters. Thus, for example, a rAAV comprising a heterologous nucleic acid encoding a heterologous gene product is a rAAV comprising nucleic acid not normally comprised in a naturally occurring wild-type AAV, and the encoded heterologous gene product is a gene product not normally encoded by a naturally occurring wild-type AAV.
As used herein, the terms "peptide," "peptide," and "protein" refer to a polymer of amino acids of any length. The term also encompasses amino acid polymers that have been modified; for example, disulfide bond formation, glycosylation, lipidation, phosphorylation or conjugation to a labeling component.
As used herein, an "expression vector" encompasses a vector, such as a plasmid, a microring, a viral vector, a liposome, etc., as discussed above or as known in the art, and is used to effect expression of a gene product in a desired target cell, the vector comprising a polynucleotide encoding the gene product of interest. The expression vector further includes a control element operably linked to the coding region to facilitate expression of the gene product in the target. Combinations of control elements such as promoters, enhancers, UTRs, miRNA targeting sequences, and the like, and one or more genes operably linked thereto for expression are sometimes referred to as "expression cassettes. Many such control elements are known and available in the art or can be readily constructed from components available in the art.
The term "endogenous" as used herein with respect to a nucleotide molecule or gene product refers to a nucleic acid sequence, e.g., a gene or genetic element, or a gene product, e.g., RNA, protein, naturally occurring in or associated with a host virus or cell.
As used herein, the term "native" refers to the presence of a nucleotide sequence, e.g., a gene, or a gene product, e.g., RNA, protein, in a wild-type virus or cell.
As used herein, the term "administering" or "introducing" refers to delivering a vector for recombinant gene or protein expression to a cell, a cell and/or organ of a subject, or a subject. Such administration or introduction may occur in vivo, in vitro, or ex vivo. The vector for expressing the gene product may be introduced into the cell by: transfection, which generally means insertion of heterologous DNA into a cell by physical means (e.g., calcium phosphate transfection, electroporation, microinjection, or lipofection); infection, which generally refers to the introduction by an infectious agent, i.e., a virus; or transduction, which generally means the stable infection of a cell with a cell or the transfer of genetic material from one microorganism to another by a viral agent (e.g., a bacteriophage).
As used herein, the term "host cell" refers to a cell that has been transduced, infected, transfected or transformed with a vector. The vector may be a plasmid, a viral particle, a phage, or the like. The culture conditions of the host cells, such as temperature, pH, etc., will be apparent to those skilled in the art. It is understood that the term "host cell" refers to the initially transduced, infected, transfected or transformed cell and its progeny.
The term "treatment (TREATMENT, TREATING, etc)" is generally used herein to mean obtaining a desired pharmacological and/or physiological effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof, e.g., reducing the likelihood of developing a disease or symptom thereof in a subject, and/or may be therapeutic in terms of partially or completely curing a disease and/or adverse effects caused by a disease. As used herein, "treating" covers any treatment of a disease in a mammal and includes: (a) Preventing the disease from occurring in a subject who may be predisposed to having the disease but has not yet been diagnosed as having the disease; (b) inhibiting disease, i.e., arresting disease progression; or (c) alleviating the disease, i.e., causing regression of the disease. The therapeutic agent may be administered before, during or after the onset of the disease or injury. Of particular interest is the treatment of developing diseases, wherein the treatment stabilizes or reduces undesirable clinical symptoms in the patient. It is desirable to perform such treatment before the function of the affected tissue is completely lost. Ideally, the subject treatment will be administered during and in some cases after the symptomatic phase of the disease.
The terms "individual," "host," "subject," and "patient" are used interchangeably herein and refer to mammals, including but not limited to humans and non-human primates, including: simian and human; mammalian sports animals (e.g., horses); mammalian farm animals (e.g., sheep, goats, etc.); mammalian pets (dogs, cats, etc.); and rodents (e.g., mice, rats, etc.).
The adeno-associated viral capsid proteins of the application and their uses are illustrated by the following specific examples. The following examples are only illustrative of the present application and should not be construed as limiting the scope of the application. The plasmids referred to in the examples below are all known to those skilled in the art. The examples are not to be construed as limiting the specific techniques or conditions described in the literature in this field or as per the specifications of the product. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
The practice of the present application will employ, unless otherwise indicated, conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry and immunology, which are within the skill of the art. This technique is well explained in the literature, as in molecular cloning: laboratory Manual (Molecular Cloning: A Laboratory Manual) second edition (Sambrook et al, 1989); oligonucleotide Synthesis (Oligonucleotide Synthesis) (M.J.Gait, eds., 1984); animal cell Culture (ANIMAL CELL Culture) (r.i. freshney, 1987); enzymatic methods (Methods in Enzymology) (academic Press Co., ltd.); manual of laboratory immunology (Handbook of Experimental Immunology) (D.M. Weir & C.C. Blackwell); mammalian cell gene transfer Vectors (GENE TRANSFER Vectors for MAMMALIAN CELLS) (J.M.Miller & M.P.Calos, eds., 1987); molecular biology laboratory guidelines (Current Protocols in Molecular Biology) (F.M. Ausubel et al, 1987); PCR: polymerase chain reaction (PCR: the Polymerase Chain Reaction) (Mullis et al, 1994); and immunology laboratory Manual (Current Protocols in Immunology) (J.E. Coligan et al, 1991), each of which is incorporated herein by reference.
In a first aspect, the application provides a non-naturally occurring modified adeno-associated virus (AAV) capsid protein comprising the amino acid sequence shown in SEQ ID No. 1.
In a second aspect, the application provides a polynucleotide molecule comprising at least one of the nucleotide sequences encoding the AAV capsid proteins provided in the first aspect of the application or the complement thereof; preferably, the polynucleotide molecule comprises the nucleotide sequence shown in SEQ ID NO. 3.
In some embodiments, the polynucleotide molecule further comprises an intron that facilitates increasing the expression efficiency of the capsid protein.
In a third aspect the application provides an expression vector comprising a polynucleotide molecule provided in accordance with the second aspect of the application, wherein the polynucleotide molecule is operably linked to a promoter sequence.
In some embodiments, the promoter is a tissue-specific promoter that preferentially drives expression in one or more tissues or cell types, such as the retina.
In some embodiments, the expression vector further comprises a sequence encoding a rep protein, such as an AAV2 rep protein.
In a fourth aspect, the application provides a cell comprising a polynucleotide molecule provided in accordance with the second aspect of the application or an expression vector provided in accordance with the third aspect of the application.
In some embodiments, the cell is a helper cell or host cell, such as a HEK293 cell that can be used to produce a viral particle comprising a capsid protein of the application. In preparing viral particles comprising AAV capsid proteins of the application, any host cell useful for producing rAAV viral particles may be employed, including, for example, mammalian cells (e.g., 293 cells), insect cells (e.g., sf9 cells), microorganisms, and yeast. The host cell may also be a packaging cell in which the AAV rep and cap genes are stably maintained in the host cell or a production cell in which the AAV vector genome is stably maintained and packaged. Exemplary packaging and production cells are derived from Sf-9, 293, a549 or HeLa cells. AAV vectors are purified and formulated using standard techniques known in the art.
In some embodiments, the cell further comprises a polynucleotide encoding a therapeutic protein.
In some embodiments, the cell further comprises a polynucleotide encoding a rep protein.
In a fifth aspect the present application provides a recombinant virus or viral vector comprising an adeno-associated viral capsid protein as provided in the first aspect of the application.
In some embodiments, the recombinant virus or viral vector may be selected from adenovirus, adeno-associated virus (AAV), lentivirus, herpesvirus, alphavirus, or retrovirus, such as moloney murine leukemia virus (MMuLV), moloney murine sarcoma virus (MoMSV), havena murine sarcoma virus (hamus v), murine mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline Leukemia Virus (FLV), foamy virus, frank murine leukemia virus, murine Stem Cell Virus (MSCV), and Rous Sarcoma Virus (RSV) or lentivirus. Although the following describes in more detail examples covering the use of adeno-associated viruses, it is contemplated that those of ordinary skill in the art will appreciate that similar knowledge and techniques in the art may also be used for non-AAV gene therapy vectors. See, for example, the discussion of retroviral vectors in, for example, U.S. patent No. 7,585,676 and U.S. patent No. 8,900,858, and the discussion of adenoviral vectors in, for example, U.S. patent No. 7,858,367. In some embodiments, the recombinant virus or viral vector is infectious. In some embodiments, the recombinant virus or viral vector has replication capacity. In some embodiments, the recombinant virus or viral vector is not replication competent. In some embodiments, the recombinant virus or viral vector is an AAV; more preferably, the AAV is AAV2.
In some embodiments, the recombinant virus or viral vector is capable of binding and crossing the Inner Limiting Membrane (ILM) when intravitreally or suprachoroidal space is injected into a mammal.
In some embodiments, the recombinant virus or viral vector comprises a polynucleotide sequence encoding a therapeutic gene product; preferably, the therapeutic gene product is anti-vascular endothelial growth factor (anti-VEGF).
In some embodiments, the recombinant virus or viral vector is an AAV further comprising an expression cassette comprising a polynucleotide sequence encoding the therapeutic gene product. In certain embodiments, the polynucleotide sequence encoding the gene product is operably linked to a promoter sequence. In certain embodiments, the expression cassette is flanked at the 5 'and 3' ends by functional AAV Inverted Terminal Repeat (ITR) sequences. In some embodiments, the AAV ITRs can be derived from any of several AAV serotypes, such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, and AAV10. Some AAV vectors have all or part of the wild type REP and CAP genes deleted, but retain functional ITR sequences.
In some embodiments, the therapeutic gene product is an interfering RNA. In some embodiments, the therapeutic gene product is an aptamer. In some embodiments, the therapeutic gene product is a polypeptide. In some embodiments, the therapeutic gene product is a site-specific nuclease for site-specific knockdown of gene function.
Where the gene product is interfering RNA (RNAi), suitable RNAi includes RNAi that reduces the level of apoptotic or angiogenic factors in the cell. For example, RNAi can be shRNA or siRNA that reduces the level of gene products in a cell that induce or promote apoptosis. The interfering RNA may also be an interfering RNA directed against an angiogenesis product, such as VEGF.
Where the gene product is an aptamer, exemplary aptamers of interest include aptamers to Vascular Endothelial Growth Factor (VEGF). See, e.g., ng et al (2006) [ natural review: drug discovery (Nat. Rev. Drug discovery) 5:123; lee et al (2005) Proc. Natl. Acad. Sci. USA, 102:18902. Also suitable for use are P D G F specific aptamers, such as E1 003 0; see, e.g., N i and H u i (20 0 9) journal of ophthalmology (Ophthalmologica) 223:401; akiyama et al (2006) journal of cell physiology (J.cell Physiol.) 207:407.
Where the gene product is a polypeptide, in certain embodiments, the polypeptide may enhance the function of a retinal cell, e.g., a rod or cone photoreceptor cell, a retinal ganglion cell, a Muller cell, a bipolar cell, an amacrine cell, a horizontal cell, or a retinal pigment epithelial cell. Exemplary polypeptides include: neuroprotective polypeptides (e.g., GDNF, CNTF, NT4, NGF, and NTN); anti-angiogenic polypeptides (e.g., soluble Vascular Endothelial Growth Factor (VEGF) receptor, VEGF binding antibody fragment (e.g., single chain anti-VEGF antibody), endostatin, tumor chalone, angiochalone, soluble Flt polypeptide, fc fusion protein including soluble Flt polypeptide, pigment Epithelium Derived Factor (PEDF), soluble Tie-2 receptor, tissue metalloproteinase inhibitor-3 (TIMP-3), light responsive opsin such as rhodopsin, anti-apoptotic polypeptides (e.g., bcl-2, bcl-Xl), etc. suitable polypeptides include, but are not limited to, glial-derived neurotrophic factor (GDNF), fibroblast growth factor 2, neurturin (NTN), ciliary neurotrophic factor (CNTF), nerve Growth Factor (NGF), neurotrophin-4 (NT 4), brain Derived Neurotrophic Factor (BDNF), rhodopsin, X-linked apoptosis inhibitor, and sonic hedgehog, as well as polypeptides having a functionality at least as variants at least as at least one of at least 60%, at least about 80%, or at least about 60% of the same, or at least about a 60% of the sequence of any of these polypeptides.
In some embodiments, the therapeutic gene product is a site-specific nuclease for site-specific knockdown of gene function, e.g., the nuclease knocks out alleles associated with retinal disease.
In addition to knocking out the defective allele, the site-specific nuclease may also be used to stimulate homologous recombination with donor DNA encoding a functional copy of the protein encoded by the defective allele. For example, the recombinant virus or viral vector can be used to both deliver a site-specific endonuclease that knocks out the defective allele, and also to deliver a functional copy of the defective allele, thereby repairing the defective allele, thereby providing for the production of functional retinal proteins (e.g., functional retinal cleaving protein, functional RPE65, functional peripheral protein, etc.). In some embodiments, the recombinant virus or viral vector may comprise: a heterologous nucleotide sequence encoding a site-specific endonuclease; and a heterologous nucleotide sequence encoding a functional copy of the defective allele, wherein the functional copy encodes a functional retinal protein. Functional retinal proteins include, for example, retinal cleaving protein, RPE65, retinitis pigmentosa GTPase regulator (RGPR) interacting protein-1, peripheral proteins, peripheral protein-2, and the like.
In some embodiments, the nucleotide sequence encoding the therapeutic gene product is operably linked to a constitutive promoter. In some embodiments, the nucleotide sequence encoding the therapeutic gene product is operably linked to an inducible promoter. In some embodiments, the nucleotide sequence encoding the therapeutic gene product is operably linked to a tissue-specific or cell-type-specific regulatory element. In some embodiments, the promoter is selected from the group consisting of a Cytomegalovirus (CMV) promoter, a Rous Sarcoma Virus (RSV) promoter, an MMT promoter, an EF-1 a promoter, a UB6 promoter, a chicken β -actin promoter, a CAG promoter, an RPE65 promoter, and an opsin promoter.
In some embodiments, the nucleotide sequence encoding the therapeutic gene product is operably linked to a photoreceptor-specific regulatory element (e.g., a photoreceptor-specific promoter), e.g., a regulatory element that confers selective expression of the operably linked gene in photoreceptor cells. Suitable photoreceptor-specific regulatory elements include, for example: a rhodopsin promoter; rhodopsin kinase promoter, beta phosphodiesterase Gene promoter (Nicoud et al (2007) Gene medicine (Gene med.)) 9:1015; retinal pigment degeneration gene promoters (NiCoad et al (2007) supra); an inner photoreceptor retinoid binding protein (IRBP) gene enhancer (NiCoad et al (2007) supra); IRBP gene promoter (Yokoyama et al (1992) experimental ophthalmic study (Exp Eye Res.) 55:225) and the like.
Recombinant viruses or viral vectors comprising the adeno-associated viral capsid proteins of the application can be produced using standard methods. For example, an AAV expression vector comprising an expression cassette may be introduced into a producer cell, followed by an AAV helper construct comprising a nucleotide sequence encoding an adeno-associated viral capsid protein of the application, and wherein the helper construct comprises an AAV coding region capable of expression in the producer cell and complementing AAV helper functions lacking in the AAV vector. Subsequently introducing a helper virus and/or an additional vector into the producer cell, wherein the helper virus and/or the additional vector provides a helper function capable of supporting efficient production of said recombinant virus or viral vector. The producer cells are then cultured to produce the recombinant virus or viral vector. These steps are performed using standard methods. Replication defective AAV viral particles comprising the adeno-associated viral capsid proteins of the application are made by standard techniques known in the art using AAV packaging cells and packaging techniques. Examples of such methods may be found, for example, in U.S. patent nos. 5,436,146, 5,753,500, 6,040,183, 6,093,570, and 6,548,286, which are expressly incorporated herein by reference in their entirety. Additional compositions and methods for packaging are described in Wang et al (US 2002/0168342), also incorporated by reference in its entirety.
In some embodiments, a recombinant virus or viral vector comprising a mutated capsid protein described herein has an increased expression of a protein of interest in vitro or in vivo of at least 10%, at least 20%, at least 30%, at least 40%, at least 50% at least 60%, at least 70%, at least 80%, at least 90% as compared to a corresponding recombinant virus or viral vector not comprising a capsid protein comprising said mutation.
In some embodiments, a recombinant virus or viral vector comprising a mutated capsid protein described herein is capable of selectively transducing retinal cells at higher levels at which it transduces one or more other ocular cell types.
In a sixth aspect, the application provides a pharmaceutical composition comprising a recombinant virus or viral vector as provided in the fifth aspect of the application and a pharmaceutically acceptable carrier and/or excipient.
The recombinant viruses or viral vectors of the application may be combined with pharmaceutically acceptable carriers, additives and excipients for primate use, especially human use. In some embodiments, the excipient may be a solid, liquid, semi-solid, or aerosol composition. Examples of carriers include, but are not limited to, water, saline, ringer's solution, dextrose solution, and 5% human serum albumin. Additives may also be included in the pharmaceutical composition, such as: sterile diluents, such as water for injection, saline solutions, non-volatile oils, polyethylene glycols, glycerol, propylene glycol or other synthetic solvents; antibacterial compounds such as benzyl alcohol or methylparaben; antioxidants such as ascorbic acid or sodium bisulfite; chelating compounds such as ethylenediamine tetraacetic acid (EDTA); buffers such as acetate, citrate or phosphate; detergents such as Tween 20 (Tween 20) for preventing polymerization; and compounds for modulating tonicity, such as sodium chloride or dextrose. The pH may be adjusted with an acid or base such as hydrochloric acid or sodium hydroxide. In some embodiments, the pharmaceutical composition is sterile. In the case where ocular cells are to be contacted in vivo, the gene delivery vehicle of the present application may be suitably treated for delivery to the eye.
In some embodiments, the pharmaceutical composition may further comprise a sterile aqueous solution or dispersion and/or a sterile powder for extemporaneous preparation of a sterile injectable solution or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water or Phosphate Buffered Saline (PBS). In some embodiments, the pharmaceutical composition is sterile and should have a fluidity to the extent that easy injection occurs. In some embodiments, the pharmaceutical composition is stable under manufacturing and storage conditions and is preserved against contamination by microorganisms such as bacteria and fungi. In some embodiments, the carrier may also be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycols, and the like), and suitable mixtures thereof. For example, proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In some embodiments, isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride may also be included in the pharmaceutical composition. In some embodiments, prolonged absorption of the pharmaceutical composition may be achieved by including agents that delay absorption, such as aluminum monostearate and gelatin, in the pharmaceutical composition.
Sterile solutions can be prepared by incorporating the recombinant virus or viral vector in the required amount in the appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the methods of preparation are typically vacuum-drying and/or freeze-drying.
In some embodiments, the pharmaceutical composition is prepared with a carrier that protects the recombinant virus or viral vector from rapid elimination from the body, such as a controlled release formulation, comprising an implant and a microencapsulated delivery system. Biodegradable biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid may be used. Methods for preparing such formulations will be apparent to those skilled in the art. Materials are also commercially available. Liposomal suspensions (comprising liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
It may be advantageous to formulate oral, ocular or parenteral compositions in unit dosage form for ease of administration and uniformity of dosage. As used herein, a unit dosage form refers to physically discrete units suitable as unitary dosages for subjects to be treated; each unit contains a predetermined amount of the active compound (e.g., a recombinant virus or viral vector of the application or an expressed therapeutic gene product thereof) calculated to produce the desired therapeutic effect in association with the desired pharmaceutical carrier. The specifications of the unit dosage forms referred to in the present application are determined by the unique characteristics of the active compound, the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such active compounds for use in treating an individual.
Any concentration of viral particles suitable for efficiently transducing mammalian cells can be prepared. For example, the concentration of the viral particles may be configured to be 10 8 vector genomes per milliliter or more, e.g., 5×10 8 vector genomes per milliliter; 10 9 vector genomes per ml; 5×10 9 vector genomes per ml, 10× 10 10 vector genomes per ml, 5×10 10 vector genomes per ml; 10 11 vector genomes per ml; 5X 10 11 vector genomes per milliliter; 10 12 vector genomes per ml; 5X 10 12 vector genomes per milliliter; 10 13 vector genomes per ml; 1.5X10 13 vector genomes per ml; 3×10 13 vector genomes per ml; 5X 10 13 vector genomes per milliliter; 7.5X10 13 vector genomes per ml; 9X 10 13 vector genomes per ml; 1X 10 14 vector genomes per milliliter, 5X 10 14 vector genomes per milliliter or more, but typically no more than 1X 10 15 vector genomes per milliliter.
The viral vectors of the application may be formulated in any suitable unit dose, including but not limited to 1×10 8 vector genomes or more, for example 1×10 9, 1×10 10, 1×10 11, 1×10 12 or 1×10 13 vector genomes or more, in some cases 1×10 14 vector genomes, but generally no more than 4×10 15 vector genomes. In some cases, the unit dose is up to about 5×10 15 vector genomes, e.g., 1×10 14 vector genomes or less, e.g., 1×10 13, 1×10 12, 1×10 11, 1×10 10, or 1×10 9 vector genomes or less, in some cases 1×10 8 vector genomes or less, and typically not less than 1×10 8 vector genomes. In some cases, the unit dose is from 1×10 10 to 1×10 11 vector genomes. In some cases, the unit dose is 1×10 10 to 3×10 12 vector genomes. In some cases, the unit dose is 1×10 9 to 3×10 13 vector genomes. In some cases, the unit dose is 1×10 8 to 3×10 14 vector genomes.
In some embodiments, the unit dose of the pharmaceutical composition may be measured using the multiplicity of infection (MOI). MOI refers to the ratio or fold of vector or viral genome to cells to which nucleic acid can be delivered. In some embodiments, the MOI may be 1×10 6. In some embodiments, the MOI may be 1×10 5-1×107. In some embodiments, the MOI may be 1×10 4-1×108. In some embodiments, the recombinant viruses of the application have a MOI of at least about 1×101、1×102、1×103、1×104、1×105、1×106、1×107、1×108、1×109、1×1010、1×1011、1×1012、1×1013、1×1014、1×1015、1×1016、1×1017 and 1X 10 18. In some embodiments, the MOI of the recombinant viruses of the application is from 1x 10 8 to 3 x 10 14. In some embodiments, the MOI of the recombinant viruses of the application is at most about 1×101、1×102、1×103、1×104、1×105、1×106、1×107、1×108、1×109、1×1010、1×1011、1×1012、1×1013、1×1014、1×1015、1×1016、1×1017 and 1x 10 18.
In some embodiments, the amount of the pharmaceutical composition comprises from about 1×10 8 to about 1×10 15 recombinant viruses, from about 1×10 9 to about 1×10 14 recombinant viruses, from about 1×10 10 to about 1×10 13 recombinant viruses, or from about 1×10 11 to about 3×10 12 recombinant viruses.
The pharmaceutical composition may be contained in a container, package or dispenser, such as a syringe, e.g., a drug-loaded syringe, along with instructions for administration.
The pharmaceutical compositions of the present application encompass any pharmaceutically acceptable salt, ester or salt of such an ester, or any other compound capable of providing a biologically active metabolite or residue thereof, directly or indirectly upon administration to an animal, including a human.
Pharmaceutically acceptable salts are known in the art and are described, for example, in the following documents: the university of Remington's Pharmaceutical Sciences, 17 th edition, alfonso R. Gennaro (incorporated), inc. (Mark Publishing Company, easton, pa., USA), 1985 (and its recent versions); encyclopedia of pharmaceutical technology (Encyclopedia of Pharmaceutical Technology), 3 rd edition, james Swarbrick (code), U.S. inflight health care (inc.) (Informa Healthcare USA (inc.), NY, USA), 2007; pharmaceutical science (J.Pharm.Sci.) 66:2 (1977). In addition, for suitable salts, see Stahl and Camille handbook of pharmaceutically acceptable salts: properties, selection and Use (Handbook of Pharmaceutical Salts: properties, selection, and Use) (Wiley-VCH Co., 2002).
Pharmaceutically acceptable base addition salts may be formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Metals used as cations include sodium, potassium, magnesium, calcium, and the like. Amines include N-N' -dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, e.g., berge et al, pharmaceutically acceptable salts (Pharmaceutical Salts), (j. Pharma Sci), 1977,66,119). Base addition salts of acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in a conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and separating the free acid in a conventional manner. The free acid forms differ slightly from their respective salt forms in certain physical properties, such as solubility in polar solvents.
In some embodiments, the expression vectors or recombinant viruses or viral vectors of the present application may be formulated in a non-toxic inert pharmaceutically acceptable aqueous carrier, preferably at a pH in the range of 3 to 8, more preferably in the range of 6 to 8.
In some embodiments, the pharmaceutical compositions provided herein include buffers such as Phosphate Buffered Saline (PBS) or sodium phosphate/sodium sulfate, tris buffer, glycine buffer, sterile water, and other buffers known to those of ordinary skill in the art, such as those described in Good (1966) Biochemistry (5:467). In some embodiments, the pH of the buffer may range from 6.5 to 7.75, preferably from 7 to 7.5 and most preferably from 7.2 to 7.4. The pharmaceutical compositions may be formulated for various types of delivery, including, for example, ocular delivery, intravitreal injection, intraocular injection, retinal injection, subretinal injection, suprachoroidal injection, parenteral administration, intravenous injection or infusion, and injection into the liver.
The seventh aspect of the application provides the use of an adeno-associated viral capsid protein of the first aspect of the application, a polynucleotide molecule of the second aspect of the application, an expression vector of the third aspect of the application, a cell of the fourth aspect of the application, a recombinant virus or viral vector of the fifth aspect of the application or a pharmaceutical composition of the sixth aspect of the application in the manufacture of a medicament for the treatment of neovascular ocular disease.
The neovascular ocular disease referred to in the present application refers to ocular diseases associated with neoblood vessels, and in some embodiments, the neovascular ocular disease is selected from at least one of age-related macular degeneration (AMD), wet AMD, dry AMD, retinal neovascularization, choroidal neovascularization, diabetic retinopathy, proliferative diabetic retinopathy, retinal vein occlusion, central retinal vein occlusion, branch retinal vein occlusion, diabetic macular edema, diabetic retinal ischemia, ischemic retinopathy, and diabetic retinal edema.
The eighth aspect of the application also provides a method of treating or preventing ocular neovascular diseases comprising administering to a subject a recombinant virus or viral vector of the fifth aspect of the application or a pharmaceutical composition of the sixth aspect of the application by intravitreal injection or suprachoroidal injection.
The recombinant viruses or viral vectors described herein comprising the capsid proteins of the application can be used to deliver transgenes to cells, such as cells of animals. The recombinant viruses or viral vectors of the application are scientifically studied or used for medical purposes. In some embodiments of the application, methods of expressing a gene in a cell are provided, the methods comprising contacting the cell with an expression vector or recombinant virus or viral vector or pharmaceutical composition of the application. In some embodiments, the contacting occurs in vitro. In some embodiments, the contacting occurs in vivo, i.e., the expression vector or recombinant virus or viral vector or pharmaceutical composition of the application is administered to the subject. In some embodiments, the administration is parenteral, e.g., intravenous, oral, or by injection. In some embodiments, the expression vector or recombinant virus or viral vector or pharmaceutical composition may be administered to the eye by injection, for example, to the retina, subretinal, suprachoroidal space, or vitreous. In some embodiments, the expression vector or recombinant virus or viral vector or pharmaceutical composition is administered by retinal injection, subretinal injection, suprachoroidal injection, or intravitreal injection.
In some embodiments, to facilitate expression of the transgene, the recombinant virus or viral vector or expression vector comprising the mutated capsid protein is contacted with the cell for about 30 minutes to 24 hours or more, such as 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 12 hours, 16 hours, 18 hours, 20 hours, 24 hours, and the like. Recombinant viruses or viral vectors or expression vectors comprising mutated capsid proteins may be provided to the cells one or more times, e.g. once, twice, three times or more than three times, and the cells may be allowed to incubate with one or more agents after each such contact, e.g. 16-24 hours, for an amount of time after which the medium is replaced with fresh medium and the cells are further cultured. Contacting the cells may occur in any medium, and/or under any culture conditions that promote cell survival. For example, the cells may be suspended in any suitable nutrient medium, such as Iscove's modified DMEM or RPMI 1640, which may be supplemented with fetal bovine serum or heat-inactivated goat serum (about 5-10%), L-glutamine, thiols, particularly 2-mercaptoethanol, and antibiotics, such as penicillin and streptomycin. The medium may contain growth factors to which the cells respond. Illustrative examples of growth factors include polypeptide and non-polypeptide factors.
In some embodiments, an effective amount of a recombinant virus or viral vector or expression vector comprising a capsid protein of the application is provided such that the transgene is expressed in the cell. In some embodiments, an effective amount can be readily determined empirically, e.g., by detecting the presence or level of a transgene product, by detecting the effects of viability or function of a cell, and the like.
In some embodiments, where the cells are contacted in vivo with a recombinant virus or viral vector or expression vector comprising a capsid protein of the application, the subject may be any mammal, e.g., a rodent (e.g., mouse, rat, gerbil), rabbit, feline, canine, goat, ovine, porcine, equine, bovine, or primate. In some embodiments, the methods and pharmaceutical compositions of the application are useful for treating any condition that may be at least partially addressed by cellular gene therapy. In some embodiments, the pharmaceutical compositions and methods of the application are useful for treating an individual in need of cell therapy. Cells include, but are not limited to, blood, eyes, liver, kidneys, heart, muscle, stomach, intestines, pancreas, and skin.
In some embodiments, the methods comprise administering to a subject by ocular injection a pharmaceutical composition comprising a recombinant virus or viral vector described herein, wherein the recombinant virus comprises a capsid protein as disclosed herein and a polynucleotide sequence encoding a gene product. In some embodiments, the retinal cell may be a photoreceptor cell, a retinal ganglion cell, a Muller cell, a bipolar cell, an amacrine cell, a horizontal cell, or a retinal pigment epithelial cell. In some cases, the retinal cell is a photoreceptor cell, such as a rod cell or cone cell. In some embodiments, the delivery is by intravitreal injection, retinal injection, suprachoroidal injection, or subretinal injection.
In some embodiments, the application provides methods of treating or preventing neovascular eye disease comprising administering to one or both eyes of a subject a pharmaceutical composition of the application, e.g., by intravitreal injection or suprachoroidal injection
Neovascular eye diseases that can be treated using the methods of the application include, but are not limited to: acute macular neuropathy; behcet's disease; choroidal neovascularization; diabetic uveitis; histoplasmosis; macular degeneration, such as acute macular degeneration, non-exudative age-related macular degeneration, and exudative age-related macular degeneration; oedema, such as macular oedema, cystoid oedema and diabetic macular oedema; multifocal choroiditis; ocular trauma, which affects the posterior site or location of the eye; eye tumors; retinal disorders such as central retinal vein occlusion, diabetic retinopathy (including proliferative diabetic retinopathy), proliferative Vitreoretinopathy (PVR), retinal arterial occlusive disease, retinal detachment and uveal inflammatory retinal disease; sympathogenic ophthalmia; vogue-salix-primordial three's (Vogt Koyanagi-Harada) (VKH) syndrome; spreading grape membranes; a post-ocular condition caused by or affected by ocular laser treatment; a post-ocular condition caused by or affected by photodynamic therapy; photocoagulation and radiation retinopathy; disorders of the pre-retinal membrane; retinal branch vein occlusion; anterior ischemic optic neuropathy; diabetic retinal dysfunction without retinopathy; retinal cleavage; retinitis pigmentosa; glaucoma; wu Xieer syndrome, cone-rod malnutrition; stuttgart's disease (yellow spotted fundus); hereditary macular degeneration; choroidal retinal degeneration; leber congenital amaurosis; congenital stationary night blindness; no choroid; barbita syndrome; macular telangiectasia; leber hereditary optic neuropathy; retinopathy of prematurity; and color vision disorders, including total, red, green, and blue color blindness.
In some embodiments, the subject has been diagnosed as having or suspected of being at risk of developing one or more diseases or conditions selected from the group consisting of: age-related macular degeneration (AMD), wet AMD, dry AMD, retinal neovascularization, choroidal neovascularization, diabetic retinopathy, proliferative diabetic retinopathy, retinal vein occlusion, central retinal vein occlusion, branch retinal vein occlusion, diabetic macular edema, diabetic retinal ischemia, ischemic retinopathy, and diabetic retinal edema. In certain embodiments, the gene product inhibits a neovascularization, such as Choroidal Neovascularization (CNV), in the retina of the subject. Many cytokines have been found to play an important role in regulating CNV production, which may include, but are not limited to, vascular Endothelial Growth Factor (VEGF), VEGF receptor (VEGFR), platelet-derived growth factor (PDGF), hypoxia-inducible factor (HIF), angiopoietin (Ang) and other cytokines, mitogen-activated protein kinase (MAPK). In particular embodiments, the gene product inhibits one or more of these cytokines.
In some embodiments, the recombinant virus or viral vector-produced gene product comprised in the pharmaceutical compositions of the application is an anti-VEGF protein or VEGF antagonist, such as, but not limited to, the VEGF binding proteins or functional fragments thereof disclosed in U.S. patent nos. 5,712,380, 5,861,484, and 7,071,159, and the VEGF binding fusion proteins disclosed in U.S. patent No. 7,635,474. The anti-VEGF protein may also comprise an sFLT-1 protein as described in U.S. patent application publication No. 2013/032332.
In some embodiments, the recombinant viruses or viral vectors of the application may include sequences encoding against VEGF proteins or VEGF antagonists, which refer to agents that partially or substantially reduce or inhibit the activity or production of VEGF. VEGF antagonists may directly or indirectly reduce or inhibit the activity or production of specific VEGF such as VEGF 165. In addition, VEGF antagonists that meet the above definition of "antagonist" include agents that act on the VEGF ligand or its cognate receptor to reduce or inhibit VEGF-related receptor signaling. Examples of VEGF antagonists include: antisense molecules, ribozymes or RNAi targeting VEGF nucleic acids; an anti-VEGF aptamer, an anti-VEGF antibody directed against VEGF itself or its receptor, or a soluble VEGF receptor decoy that prevents VEGF binding to its cognate receptor; antisense molecules, ribozymes or RNAi targeting homologous VEGF receptor (VEGFR) nucleic acids; an anti-VEGFR aptamer or an anti-VEGFR antibody that binds to a cognate VEGFR receptor; VEGFR tyrosine kinase inhibitors.
The term "VEGF" refers to vascular endothelial growth factor that induces angiogenesis or angiogenic processes. As used herein, the term "VEGF" encompasses VEGF of various subtypes (also referred to as Vascular Permeability Factors (VPF) and VEGF-Sub>A) produced by, for example, alternatively splicing the VEGF-Sub>A/VPF gene (see fig. 2 (Sub>A) and (B) of U.S. patent application publication No. 20120100136), including VEGF121, VEGF165, and VEGF189. Further, as used herein, the term "VEGF" encompasses VEGF-related angiogenic factors, such as PIGF (placental growth factor), VEGF-B, VEGF-C, VEGF-D, and VEGF-E, which act through the cognate VEFG receptor (i.e., VEGFR) to induce angiogenesis or angiogenic processes. The term "VEGF" encompasses any member of a class of growth factors that bind to the VEGF receptor, such as VEGFR-1 (Flt-1) (see FIGS. 4 (A) and (B) of U.S. patent application publication No. 20120100136), VEGFR-2 (KDR/Flk-1) (see FIGS. 4 (C) and (D) of U.S. patent application publication No. 20120100136), or VEGFR-3 (FLT-4). The term "VEGF" may be used to refer to a "VEGF" polypeptide or a "VEGF" encoding a gene or nucleic acid.
In some embodiments, the VEGF antagonist is Sub>A VEGF-A antagonist.
In some embodiments, the VEGF antagonist is ranibizumab, bevacizumab, aflibercumab, aflibercept, constantan (Conbercept), KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegatanib sodium (pegaptanib), bei Faxi ni (bevasiranib), SIRNA-027, decursin (decursin), decursinol (decursinol), picropodophyllin (picropodophyllin), myrrh sterone (guggulsterone), PLG101, eicosanoids LXA4, PTK787, pazopanib (pazopanib), axitinib (axitinib), CDDO-Me, CDDO-Imm, shikonin (shikonin), β -hydroxyisovaleryl shikonin (beta-hydroxyisovalerylshikonin), or ganglioside GM3, DC101 antibody, mab25 antibody, mab73, 4A5 antibody, 4E10 antibody, VA01, VEGF antibody, BL 01, and a 3, or a pharmaceutically acceptable salt thereof, flb (3402, 35), flunixin (3402, 35, or a pharmaceutically acceptable salt thereof.
In some embodiments, the VEGF antagonist is the antibody ranibizumab or a pharmaceutically acceptable salt thereof (see fig. 1 of U.S. patent No. 7,060,269, incorporated herein by reference in its entirety for heavy and light chain variable region sequences). Ranitimab is commercially available under the trademark (Roche Group) member U.S. GeneTek Co., ltd (GENENTECH USA, inc.).
In some embodiments, the VEGF antagonist is the antibody bevacizumab or a pharmaceutically acceptable salt thereof (see figure 1 of U.S. patent No. 6,054,297, incorporated herein by reference in its entirety for heavy and light chain variable region sequences). Bevacizumab is commercially available under the trademark (roche group member, inc. On gene taek, usa).
In some embodiments, the VEGF antagonist is Abelmoschus or a pharmaceutically acceptable salt thereof (Do et al (2009) [ journal of England eye (Br J Ophthalmol.)) ] 93:144-9, which is incorporated herein by reference in its entirety. Abiotic sepril is commercially available (regeneration Yuan pharmaceutical Co., ltd. (Regeneron Pharmaceuticals, inc.)).
In some embodiments, the VEGF antagonist is the naturally occurring protein sFlt-1, as described in U.S. Pat. No. 5,861,484. VEGF antagonists also include, but are not limited to, functional fragments thereof, sequences comprising sFlt-1 domain 2 or those listed in U.S. patent application publication No. 2013/0323330, and related constructs, such as VEGF binding fusion proteins disclosed in U.S. patent No. 7,635,474. The anti-VEGF protein may also comprise any of the sFLT-1 proteins, variants or fragments thereof described in U.S. patent application publication No. 2013/032332. More specifically, the VEGF binding domain (domain 2) or alternatively domain 2 of sFLT-1 plus domain 3 from sFLT1, KDR or another family member can be used to bind and inactivate VEGF. These functional fragments are described in Wiesmann et al, 1997; in cells 91:695-704, which are incorporated herein by reference in their entirety. The terms "sFLT-1" and "functional fragment of sFLT-1" are equivalent and are used interchangeably herein. By "sFlt-1 protein" is meant herein a polypeptide sequence or functional fragment thereof that is at least 90% or more homologous to a naturally occurring human sFLT-1 sequence, such that the sFlt-1 protein or polypeptide binds to VEGF and/or VEGF receptors.
These sequences may be expressed from DNA encoding such sequences using the genetic code, which is a standard technique understood by those skilled in the art. As will be appreciated by those skilled in the art, due to the degeneracy of the genetic code, anti-VEGF protein sequences can be readily expressed from a plurality of different DNA sequences.
The VEGF antagonist further comprises a nucleic acid or polypeptide homologous to any of the VEGF antagonists described herein, and a functional fragment of any of the VEGF antagonists or homologs. Homology refers to conservation of residues comprising, but not limited to, an alignment between two sequences of a functional fragment, including insertions, deletions, substitutions, pseudofragments, pseudogenes, splice variants, or artificially optimized sequences. In some cases, a VEGF antagonist may be at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99% or 100% homologous to a naturally occurring or parent VEGF antagonist. In some cases, a VEGF antagonist may be up to about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99% or 100% homologous to a naturally occurring or parent sequence.
In some embodiments, the application provides a method for administering a pharmaceutical composition comprising a viral vector of the application or a recombinant virus at a frequency of at least once every 3 months, every 6 months, every 9 months, every 12 months, every 18 months, every 24 months, or every 36 months in a human subject in need of treatment. In some embodiments, the application provides a method for administering a pharmaceutical composition comprising a viral vector of the application or a recombinant virus in a human subject in need of treatment at a frequency of up to once every 3 months, every 6 months, every 9 months, every 12 months, every 18 months, every 24 months, or every 36 months. In some embodiments, the application provides for the administration of a pharmaceutical composition comprising a viral vector or recombinant virus of the application in a human subject at a frequency of less than 3 times per year, less than twice per year, less than once per two years, or less than once per three years.
In some embodiments, expression of the transgene may be observed two months or less after administration, e.g., 4 weeks, 3 weeks, or 2 weeks or less after administration, e.g., 1 week after administration of the compositions of the application, e.g., by measuring the level of the gene product, by measuring the efficacy of the treatment, etc. In some embodiments, expression of the transgene may be observed 2 months or more, e.g., 4 months, 6 months, 8 months, or 10 months or more, in some cases 1 year or more, e.g., 2 years, 3 years, 4 years, or 5 years, in some cases more than 5 years, after administration, e.g., by measuring the level of the gene product, by measuring the efficacy of the treatment, etc.
In some embodiments, one or both eyes of the subject are each administered about 1×10 8 vector genomes or more, in some embodiments 1×10 9, 1×10 10, 1×10 11, 1×10 12, or 1×10 13 vector genomes or more, in some embodiments 1×10 14 vector genomes or more. In some embodiments, the amount of vector genome delivered is up to about 1×10 15 vector genomes, e.g., 1×10 14 vector genomes or less, e.g., 1×10 13, 1×10 12, 1×10 11, 1×10 10, or 1×10 9 vector genomes or less, in some cases 1×10 8 vector genomes, and sometimes not less than 1×10 8 vector genomes. In some embodiments, the amount of vector genome delivered is from 1 x 10 10 to 1 x 10 11 vector genomes. In some embodiments, the amount of vector genome delivered is from 1×10 10 to 3×10 12 vector genomes. In some embodiments, the amount of vector genome delivered is from 1×10 9 to 3×10 13 vector genomes. In some embodiments, the amount of vector genome delivered is from 1×10 8 to 3×10 14 vector genomes.
In some embodiments, the amount of the pharmaceutical composition to be administered may be measured using the multiplicity of infection (MOI). In some embodiments, the MOI may refer to the ratio or fold of vector or viral genome to the cell to which the nucleic acid may be delivered. In some embodiments, the MOI may be 1×10 6. In some embodiments, the MOI may be 1×10 5-1×107. In some embodiments, the MOI may be 1x 10 4 to 1x 10 8. In some embodiments, the recombinant viruses of the application have a MOI of at least about 1×101、1×102、1×103、1×104、1×105、1×106、1×107、1×108、1×109、1×1010、1×1011、1×1012、1×1013、1×1014、1×1015、1×1016、1×1017 and 1X 10 18. In some cases, the MOI of the recombinant viruses of the application is from 1x 10 8 to 3 x 10 14. In some embodiments, the MOI of the recombinant viruses of the application is at most about 1×101、1×102、1×103、1×104、1×105、1×106、1×107、1×108、1×109、1×1010、1×1011、1×1012、1×1013、1×1014、1×1015、1×1016、1×1017 and 1x 10 18.
In some embodiments, the amount of the pharmaceutical composition comprises from about 1×10 8 to about 1×10 15 recombinant virions or viruses, from about 1×10 9 to about 1×10 14 recombinant virions or viruses, from about 1×10 10 to about 1×10 13 recombinant virions or viruses, or from about 1×1011 to about 3×10 12 recombinant virions or viruses.
In some embodiments, the presence of the viral vector is detected by qPCR or ELBA as known in the art.
In some embodiments, the optimal corrected vision (BCVA) of the subject is increased by 1,2,3, 4,5 or more rows following the methods of treatment described herein.
In some embodiments, the reduction of new blood vessels as assessed by Fluorescein Angiography (FA).
In some embodiments, the retinal thickness may be measured to check the effect of the treatment. In some embodiments, the central retinal thickness of a human subject does not increase by more than 50 microns, 100 microns, or 250 microns within 12 months after treatment with the pharmaceutical composition of the present application. In some embodiments, the central retinal thickness of a human subject is reduced by at least 50 microns, 100 microns, 200 microns, 250 microns, 300 microns, 400 microns, 500 microns, 600 microns within 3 months, 6 months, 9 months, or 12 months after treatment with the pharmaceutical composition of the present application. The decrease in central retinal thickness in human subjects can be measured by comparing the central retinal thickness at the time point to baseline measurements taken at or within 1 day, 3 days, 7 days, or 10 days of administration of the pharmaceutical composition of the application.
The adeno-associated viral capsid proteins of the application and their uses are illustrated by the specific examples below. It should be understood that the examples are only for illustrating the present application and are not intended to limit the scope of the present application.
General methods of molecular and cellular biochemistry can be found in standard textbooks such as the following: molecular cloning: laboratory Manual (Molecular Cloning: A Laboratory Manual) 3 rd edition (Sambrook et al, harbor laboratory Press (HaRBor Laboratory Press) 2001); fine code molecular biology laboratory Manual (Short Protocols in Molecular Biology) 4 th edition (Ausubel et al, john Wiley father & Sons 1999); protein Methods (Bollar et al, john Willi parent 1996); gene therapy non-viral vectors (Nonviral Vectors for GENE THERAPY) (Wagner et al, academic Press 1999); viral Vectors (Kaplift & Loewy, academic Press 1995); manual of immunology methods (Immunology Methods Manual) (I.Lefkovits, academic Press 1997); cell and tissue culture: biotechnology laboratory step (Cell and Tissue Culture: laboratory Procedures in Biotechnology) (Doyle & Griffiths, john Willi parent 1998), the disclosure of which is incorporated herein by reference. Reagents, cloning vectors and kits for gene manipulation as referred to in the present application are available from commercial suppliers such as BioRad, stratagene, invitrogen, sigma-Aldrich and ClonTech.
Example 1 construction of AAV2 viral vectors
PRepCap plasmids encoding the capsid protein VP1 of wild-type AAV2, VP1 of modified AAV2 (SEQ ID NO. 2) and VP1 of AAV2 (SEQ ID NO. 1) of the present application were synthesized from Jin Weizhi according to the sequences shown in SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, respectively.
AAV shuttle plasmid vector expressing green fluorescent protein GFP was synthesized by general Gene company according to SEQ NO ID.7 sequence.
The production of AAV vector adopts a three-plasmid system, namely, uses shuttle plasmid and helper plasmid pHelper obtained above and three different pRepCap plasmids, uses PEI as transfection reagent to transfect HEK293 cells together, and respectively recombinates and packages AAV vector. Harvesting 48-72 hours after transfection, purifying the obtained solution by affinity chromatography, further purifying by anion chromatography, ultrafiltering, concentrating, and replacing buffer solution. The recombinant AAV virus vector after purification is used for determining genome titer, and is sterilized, filtered and packaged for standby.
Three GFP-expressing viral vectors with different capsid proteins were designated as AL-AAV2-GFP (wild type VP 1), AL-000-GFP (with capsid protein shown in SEQ ID NO. 2), and AL-372-GFP (with capsid protein shown in SEQ ID NO. 1), respectively.
Example 2 in vitro expression efficiency of viral vectors
HEK293 cells (cultured in DMEM medium containing 10% serum) were plated one day before transfection, preferably to a cell fusion of about 70% after 24 hours. After plating, placing the culture dish into a cell culture box with the temperature of 37 ℃ and the concentration of 5% CO 2 for 24 hours, discarding the culture medium in the original culture dish, washing the cells for 1 time by using PBS, and then adding 2 mL/dish of DMEM without serum into the culture dish; adding AAV virus suspension (MOI: 2× 4), mixing with light shaking culture medium, and culturing in cell culture oven at 37deg.C and 5% CO 2 for 6 hr; then 2mL of DMEM containing 10% serum is added into the culture dish, and the culture dish is placed into a cell incubator with the temperature of 37 ℃ and the concentration of 5% CO 2 for continuous culture for 48 hours; after 48h, the fluorescence was expressed under a fluorescence microscope, and the result is shown in FIG. 1; the results of flow cytometry analysis of the percentage of cells positive for infection in 1×10 4 cells are shown in fig. 2, and it can be seen from the graph that the positive rate of the cells infected by the expression vector containing the capsid protein of the present application can reach about 62%, which is significantly improved compared with the wild type (34%) and the capsid protein (46%) without V372L mutation, indicating that the capsid protein containing V372L mutation of the present application can improve the infection efficiency and expression efficiency of the viral vector.
Example 3 expression efficiency of AAV viral vectors after infection of the retinas of mice
1. Subretinal space injection
The subretinal space of the 2 month old C57BL/6J mice was mydriated with 1% atropine 30min before injection and mydriated again before anesthesia. The injection anesthesia is carried out by injecting 80mg/kg ketamine and 8mg/kg tolthiazine intraperitoneally, then the mice are placed in front of an animal experiment platform of an eye surgery microscope, and 0.5% (volume fraction) of procaine is dripped on the eyes of the mice for local anesthesia. In AAV virus solution, the ratio of 100: adding sodium fluorescein stock solution in a volume ratio of 1, and centrifuging and mixing at a low speed. An insulin needle is used for prepunching a small hole on the ciliary body flat part of a mouse eye, a needle head of a micro-injector is used for penetrating through the small hole and then entering the vitreous cavity of the mouse eye, at the moment, a proper amount of 2% hydroxymethyl cellulose is dripped on the mouse eye so that the fundus of the mouse can be clearly seen under a confocal laser microscope, then the needle head is continuously inserted into the subretinal space on the opposite side to avoid the lens, AAV virus with sodium fluorescein is slowly pushed in, the injection amount of each eye is 1 mu L (AAV MOI:3 multiplied by 10 9), and whether the injection into the subretinal space is judged by taking sodium fluorescein as an indicator. Mice were observed for abnormalities after surgery and were given neomycin eye ointment to prevent infection.
2. Treatment of mice eyeballs
After 2 weeks of subretinal cavity injection, the mice were sacrificed by neck breaking to obtain their eyeballs, the eyeballs were placed in a 1.5mL EP tube containing 1mL 4% paraformaldehyde overnight at 4 ℃, the fixed eyeballs were cut off from the cornea along the limbus under a split microscope, the lenses and vitreous bodies were removed to form a vision cup, and then gradient dehydration was performed using 20% (w/v) sucrose and 30% (w/v) sucrose solutions, respectively, and the dehydration was completed after the eyeballs were sinking. The eyes of the mice are placed in an EP tube of 1.5mL which is provided with a frozen embedding agent OCT, the eyes of the mice are put into a direction in front of direct vision by forceps, the EP tube is covered, the mice are placed into gaseous liquid nitrogen, and frozen sections can be carried out after the mice are completely frozen, wherein the section thickness is 6 mu m. Fixing with acetone at 4deg.C for 10min, and storing at-80deg.C.
3. Immunofluorescent staining and image acquisition
Taking out the frozen slices, and washing with PBS for 3 times and 5min each time after the slices are restored to room temperature; the tissue-free part of the slide is wiped dry as much as possible, 40 mu L of sealing liquid is dripped into each slice, and the slide is sealed for 30min at room temperature. After 3 times of PBS washing, DAPI diluent is dripped to dye the nuclei (1:5000), and the nuclei are incubated for 15min at room temperature. Dropping anti-fluorescence quenching sealing tablet into the glass slide, covering with cover glass, and storing at-20deg.C in dark place. The fluorescence of GFP protein was observed by Nikon A1 laser confocal microscope and photographed, and the results are shown in FIG. 3, where NC represents a blank control, i.e., the eyeballs of mice not subjected to virus infection, RPE: retinal pigment epithelium; ONL: an outer retinal nuclear layer; INL: a retinal kernel layer; GCL: retinal ganglion cell layers. As can be seen from fig. 3, after the virus vector infects the eyeballs of mice, the green fluorescent protein GFP is mainly expressed in the retinal pigment epithelium layer, and the expression amount of GFP in the RPE layer is obviously higher than that of the virus vector containing the V372L mutant capsid protein, which indicates that the V372L mutant capsid protein of the present application can obviously improve the expression efficiency of the target protein in vivo, especially in the eyeballs.
From the results, the AAV2 capsid protein VP1 is modified, and the V372L point mutation is further introduced, so that the AAV viral vector medicament containing the capsid protein has better infection efficiency and expression efficiency.
The foregoing description of the preferred embodiments of the application is not intended to limit the application to the precise form disclosed, and any such modifications, equivalents, and alternatives falling within the spirit and scope of the application are intended to be included within the scope of the application.
Claims (11)
1. An adeno-associated viral capsid protein comprising the amino acid sequence shown in SEQ ID No. 1.
2. A polynucleotide molecule comprising at least one of the nucleotide sequences encoding the adeno-associated virus capsid protein of claim 1 or the complement thereof; preferably, the polynucleotide molecule comprises the nucleotide sequence shown in SEQ ID NO. 3.
3. An expression vector comprising the polynucleotide molecule of claim 2, wherein the polynucleotide molecule is operably linked to a promoter sequence.
4. A cell comprising the polynucleotide molecule of claim 2 or the expression vector of claim 3.
5. The cell of claim 4, further comprising a polynucleotide encoding a therapeutic protein.
6. The cell of claim 4 or 5, further comprising a polynucleotide encoding a rep protein.
7. A recombinant virus or viral vector comprising the adeno-associated viral capsid protein of claim 1; preferably, the recombinant virus or viral vector is an AAV; more preferably, the AAV is AAV2.
8. The recombinant virus or viral vector according to claim 7, wherein the recombinant virus or viral vector is capable of binding to and crossing the inner limiting membrane when intravitreally or suprachoroidal space is injected into a mammal.
9. The recombinant virus or viral vector of claim 7 or 8, wherein the recombinant virus or viral vector comprises a polynucleotide sequence encoding a therapeutic gene product; preferably, the therapeutic gene product is an anti-vascular endothelial growth factor.
10. A pharmaceutical composition comprising the recombinant virus or viral vector of any one of claims 7-9, and a pharmaceutically acceptable carrier and/or excipient.
11. Use of the adeno-associated viral capsid protein of claim 1, the polynucleotide molecule of claim 2, the expression vector of claim 3, the cell of any one of claims 4-6, the recombinant virus or viral vector of any one of claims 7-9 or the pharmaceutical composition of claim 10 in the manufacture of a medicament for the treatment of neovascular eye disease; preferably, the neovascular eye disease is selected from at least one of age-related macular degeneration (AMD), wet AMD, dry AMD, retinal neovascularization, choroidal neovascularization, diabetic retinopathy, proliferative diabetic retinopathy, retinal vein occlusion, central retinal vein occlusion, branch retinal vein occlusion, diabetic macular edema, diabetic retinal ischemia, ischemic retinopathy, and diabetic retinal edema.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211567051.3A CN118146317A (en) | 2022-12-07 | 2022-12-07 | Adeno-associated virus capsid protein and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211567051.3A CN118146317A (en) | 2022-12-07 | 2022-12-07 | Adeno-associated virus capsid protein and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118146317A true CN118146317A (en) | 2024-06-07 |
Family
ID=91289241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211567051.3A Pending CN118146317A (en) | 2022-12-07 | 2022-12-07 | Adeno-associated virus capsid protein and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118146317A (en) |
-
2022
- 2022-12-07 CN CN202211567051.3A patent/CN118146317A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110650733A (en) | Modified AAV capsids and uses thereof | |
AU2017257169B2 (en) | Evasion of neutralizing antibodies by a recombinant adeno-associated virus | |
WO2022247917A1 (en) | Recombinant adeno-associated virus having variant capsid, and application thereof | |
US11072803B2 (en) | Hybrid dual recombinant AAV vector systems for gene therapy | |
US11510950B2 (en) | Variant AAV capsids for intravitreal delivery | |
US11680276B2 (en) | Compositions and methods for treating retinal disorders | |
CN118146317A (en) | Adeno-associated virus capsid protein and application thereof | |
CN117736274A (en) | Adeno-associated virus capsid protein and application thereof | |
US20230338582A1 (en) | Methods of Treating Human X-Linked Retinoschisis Using Gene Therapy | |
US20240067989A1 (en) | Compositions and Methods for Treating Retinal Disorders | |
US12065663B2 (en) | Vector and method for treating bietti's crystalline dystrophy | |
US20240035045A1 (en) | Engineered viral capsids and methods of use | |
EA046019B1 (en) | COMPOSITIONS AND METHODS FOR TREATING RETINA DISORDERS | |
CN116568815A (en) | Adeno-associated virus for ocular delivery of gene therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |